Who are Fudr's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Folic Acid, chemotherapy of mFOLFOX6 or FOLFIRI, Erlotinib, Pemetrexed, Capecitabine tablets, Placebo plus S1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/floxuridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Fudr — Competitive Intelligence Brief

Fudr (FLOXURIDINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite [EPC]. Area: Oncology.

marketed Antimetabolite [EPC] Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fudr (FLOXURIDINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fudr TARGET	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Capecitabine tablets	Capecitabine tablets	UNICANCER	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Placebo plus S1	Placebo plus S1	Chinese PLA General Hospital	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase, dihydropyrimidine dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite [EPC] class)

· 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fudr — Competitive Intelligence Brief. https://druglandscape.com/ci/floxuridine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab